Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard L Parnes

Showing results (51-60 of 110) with videos related to

Pageof 11
Sort By:
Journal of the National Cancer Institute|February 25, 2014
Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer riskAlan R Kristal, Amy K Darke, J Steven Morris, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 15, 2013
Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trialMarian L Neuhouser, Elizabeth A Platz, Cathee Till, et al.
BMC Cancer|December 17, 2025
Efficacy and toxicity of low-doses versus standard-dose enzalutamide in advanced prostate cancer. a real-world study with implications for cancer prevention/interceptionMartino Oliva, Monica Boitano, Alessio Carbone, et al.
Nutrition and Cancer|January 29, 2021
Association of Serum Carotenoids and Retinoids with Intraprostatic Inflammation in Men without Prostate Cancer or Clinical Indication for Biopsy in the Placebo Arm of the Prostate Cancer Prevention TrialSusan Chadid, Xiaoling Song, Jeannette M Schenk, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 16, 2014
Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention TrialAlan R Kristal, Cathee Till, Xiaoling Song, et al.
The Journal of Urology|December 23, 2018
Predicting Gleason Group Progression for Men on Prostate Cancer Active Surveillance: Role of a Negative Confirmatory Magnetic Resonance Imaging-Ultrasound Fusion BiopsyJonathan B Bloom, Graham R Hale, Samuel A Gold, et al.
BJU International|February 20, 2013
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancerWilliam L Dahut, Ravi A Madan, Joyson J Karakunnel, et al.
Urology|July 18, 2020
Combined MRI-targeted Plus Systematic Confirmatory Biopsy Improves Risk Stratification for Patients Enrolling on Active Surveillance for Prostate CancerLuke P O'Connor, Alex Z Wang, Nitin K Yerram, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 26, 2014
Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT)Demetrius Albanes, Cathee Till, Eric A Klein, et al.
Urologic Oncology|March 19, 2021
Risk of adverse pathology at prostatectomy in the era of MRI and targeted biopsies; rethinking active surveillance for intermediate risk prostate cancer patientsJonathan B Bloom, Michael A Daneshvar, Amir H Lebastchi, et al.
Pageof 11

Showing results (51-60 of 110) with videos related to

Sort By:
Pageof 11
Journal of the National Cancer Institute|February 25, 2014
Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer riskAlan R Kristal, Amy K Darke, J Steven Morris, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 15, 2013
Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trialMarian L Neuhouser, Elizabeth A Platz, Cathee Till, et al.
BMC Cancer|December 17, 2025
Efficacy and toxicity of low-doses versus standard-dose enzalutamide in advanced prostate cancer. a real-world study with implications for cancer prevention/interceptionMartino Oliva, Monica Boitano, Alessio Carbone, et al.
Nutrition and Cancer|January 29, 2021
Association of Serum Carotenoids and Retinoids with Intraprostatic Inflammation in Men without Prostate Cancer or Clinical Indication for Biopsy in the Placebo Arm of the Prostate Cancer Prevention TrialSusan Chadid, Xiaoling Song, Jeannette M Schenk, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 16, 2014
Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention TrialAlan R Kristal, Cathee Till, Xiaoling Song, et al.
The Journal of Urology|December 23, 2018
Predicting Gleason Group Progression for Men on Prostate Cancer Active Surveillance: Role of a Negative Confirmatory Magnetic Resonance Imaging-Ultrasound Fusion BiopsyJonathan B Bloom, Graham R Hale, Samuel A Gold, et al.
BJU International|February 20, 2013
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancerWilliam L Dahut, Ravi A Madan, Joyson J Karakunnel, et al.
Urology|July 18, 2020
Combined MRI-targeted Plus Systematic Confirmatory Biopsy Improves Risk Stratification for Patients Enrolling on Active Surveillance for Prostate CancerLuke P O'Connor, Alex Z Wang, Nitin K Yerram, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 26, 2014
Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT)Demetrius Albanes, Cathee Till, Eric A Klein, et al.
Urologic Oncology|March 19, 2021
Risk of adverse pathology at prostatectomy in the era of MRI and targeted biopsies; rethinking active surveillance for intermediate risk prostate cancer patientsJonathan B Bloom, Michael A Daneshvar, Amir H Lebastchi, et al.
Pageof 11